Stem cell harvest and engraftment
Of the 31 patients, 27 (87%) were transplant-eligible based on age ≤70 years and fitness status. Eleven (35%) proceeded to ASCT. The median duration from the start of induction to transplant was 8.5 months (5.4–12mos). The median number of cycles before ASCT was 8 (5–11), of which six were VPd, and the rest were Vd. GCSF was used in all patients, and plerixafor was used in six (55%) patients. A second session of apheresis was not required in any of the patients. Median CD34